These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35253782)

  • 1. T Lymphocytes in Parkinson's Disease.
    Contaldi E; Magistrelli L; Comi C
    J Parkinsons Dis; 2022; 12(s1):S65-S74. PubMed ID: 35253782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.
    Campos-Acuña J; Elgueta D; Pacheco R
    Front Immunol; 2019; 10():239. PubMed ID: 30828335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of T cells in the pathogenesis of Parkinson's disease.
    Chen Z; Chen S; Liu J
    Prog Neurobiol; 2018 Oct; 169():1-23. PubMed ID: 30114440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of innate and adaptive immunity in Parkinson's disease.
    Kannarkat GT; Boss JM; Tansey MG
    J Parkinsons Dis; 2013; 3(4):493-514. PubMed ID: 24275605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocyte senescence is attenuated in Parkinson's disease.
    Kouli A; Jensen M; Papastavrou V; Scott KM; Kolenda C; Parker C; Solim IH; Camacho M; Martin-Ruiz C; Williams-Gray CH
    J Neuroinflammation; 2021 Oct; 18(1):228. PubMed ID: 34645462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The key role of T cells in Parkinson's disease pathogenesis and therapy.
    Baird JK; Bourdette D; Meshul CK; Quinn JF
    Parkinsonism Relat Disord; 2019 Mar; 60():25-31. PubMed ID: 30404763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CD4+ T Cells in Parkinson's Disease.
    Ghanta MK; Nuthalapati P; Merchant N; Chenchula S; Hussain F; Ak AK; Bhaskar LVKS
    Crit Rev Immunol; 2022; 42(6):17-25. PubMed ID: 37082948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients.
    Kustrimovic N; Comi C; Magistrelli L; Rasini E; Legnaro M; Bombelli R; Aleksic I; Blandini F; Minafra B; Riboldazzi G; Sturchio A; Mauri M; Bono G; Marino F; Cosentino M
    J Neuroinflammation; 2018 Jul; 15(1):205. PubMed ID: 30001736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Tc17 cell levels and imbalance of naïve/effector immune response in Parkinson's disease patients in a two-year follow-up: a case control study.
    Álvarez-Luquín DD; Guevara-Salinas A; Arce-Sillas A; Espinosa-Cárdenas R; Leyva-Hernández J; Montes-Moratilla EU; Adalid-Peralta L
    J Transl Med; 2021 Sep; 19(1):378. PubMed ID: 34488776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Insights into Immune-Mediated Mechanisms in Parkinson's Disease.
    Tan JSY; Chao YX; Rötzschke O; Tan EK
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine Receptor D3 Expression Is Altered in CD4
    Elgueta D; Contreras F; Prado C; Montoya A; Ugalde V; Chovar O; Villagra R; Henríquez C; Abellanas MA; Aymerich MS; Franco R; Pacheco R
    Front Immunol; 2019; 10():981. PubMed ID: 31118938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-Related Adaptive Immune Changes in Parkinson's Disease.
    Kouli A; Williams-Gray CH
    J Parkinsons Dis; 2022; 12(s1):S93-S104. PubMed ID: 35661020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease.
    Contaldi E; Magistrelli L; Comi C
    Handb Clin Neurol; 2023; 193():67-93. PubMed ID: 36803824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson's Disease.
    Contaldi E; Magistrelli L; Milner AV; Cosentino M; Marino F; Comi C
    J Parkinsons Dis; 2021; 11(2):507-514. PubMed ID: 33386815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinson's diseases.
    Garfias S; Tamaya Domínguez B; Toledo Rojas A; Arroyo M; Rodríguez U; Boll C; Sosa AL; Sciutto E; Adalid-Peralta L; Martinez López Y; Fragoso G; Fleury A
    Neurologia (Engl Ed); 2022 Mar; 37(2):110-121. PubMed ID: 35279225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical correlation of peripheral CD4+‑cell sub‑sets, their imbalance and Parkinson's disease.
    Chen Y; Qi B; Xu W; Ma B; Li L; Chen Q; Qian W; Liu X; Qu H
    Mol Med Rep; 2015 Oct; 12(4):6105-11. PubMed ID: 26239429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson's disease.
    Magistrelli L; Storelli E; Rasini E; Contaldi E; Comi C; Cosentino M; Marino F
    Brain Behav Immun; 2020 Oct; 89():668-674. PubMed ID: 32688028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periphery and brain, innate and adaptive immunity in Parkinson's disease.
    Harms AS; Ferreira SA; Romero-Ramos M
    Acta Neuropathol; 2021 Apr; 141(4):527-545. PubMed ID: 33555429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research Progress of CD4
    Chen WY; Qian Y; Chen TY; Gu XP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Aug; 43(4):628-633. PubMed ID: 34494536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related biomarkers for Parkinson's disease.
    Abdi IY; Ghanem SS; El-Agnaf OM
    Neurobiol Dis; 2022 Aug; 170():105771. PubMed ID: 35598675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.